Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis.
Hiromi MatsumotoKohei SomekawaNobuyuki HoritaSuguru UedaMegumi KanekoAyami KanekoNobuhiko FukudaAmi IzawaChisato KamimakiKatsushi TanakaKota MurohashiHiroaki FujiYoichi TagamiAyako AokiKeisuke WatanabeYu HaraNobuaki KobayashTakeshi KanekoPublished in: Therapeutic advances in medical oncology (2023)
The incidence of any AE in DT therapy was approximately 78%, and the incidence of grade 3 or higher AEs was approximately 30%, which was independent of prior therapy.
Keyphrases